Milan, Italy – 20 August, 2012 – Newron Pharmaceuticals S.p.A. (“Newron”, SIX: NWRN), a research and development company focused on Central Nervous System (CNS) and pain therapies, today announced that it has successfully raised funds of approximately CHF4.7m (EUR3.9m) through a private placement. In total, 798,945 immediately tradeable shares were placed with new and existing institutional investors.
Stefan Weber, Newron’s CEO, said: “We are delighted to have the support of a strong group of international institutional investors. This is an exciting time for Newron as we look forward to regulatory submission for safinamide and focus on the next priorities in our innovative CNS pipeline.”
For more information:
Last updated on: 21/08/2012
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.